Durable, ongoing near-complete response to nivolimab + relatlimab in a 64 year old with locally-advanced BCC after resistance to 26 wks of nivolimab alone. A new study led by researchers at the Johns ...
A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of ...
A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results